DCPH Deciphera Pharmaceuticals Inc

Price (delayed)

$43.16

Market cap

$2.49B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.78

Enterprise value

$2.38B

Sector: Healthcare
Industry: Biotechnology

Highlights

Deciphera Pharmaceuticals's revenue has surged by 86% QoQ and by 68% YoY
The gross profit has soared by 86% since the previous quarter and by 67% year-on-year
The company's EPS fell by 7% YoY but it rose by 5% QoQ
The debt has surged by 77% year-on-year
The net income has contracted by 39% YoY

Key stats

What are the main financial stats of DCPH
Market
Shares outstanding
57.63M
Market cap
$2.49B
Enterprise value
$2.38B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.52
Price to sales (P/S)
57.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
56.61
Earnings
Revenue
$42.09M
EBIT
-$266.49M
EBITDA
-$261.35M
Free cash flow
-$244.99M
Per share
EPS
-$4.78
Free cash flow per share
-$4.39
Book value per share
$9.55
Revenue per share
$0.75
TBVPS
$11.52
Balance sheet
Total assets
$642.43M
Total liabilities
$98.76M
Debt
$31.22M
Equity
$543.68M
Working capital
$514.04M
Liquidity
Debt to equity
0.06
Current ratio
8.34
Quick ratio
8.08
Net debt/EBITDA
0.4
Margins
EBITDA margin
-621%
Gross margin
99.5%
Net margin
-633.2%
Operating margin
-644.4%
Efficiency
Return on assets
-39.2%
Return on equity
-44.3%
Return on invested capital
-54.4%
Return on capital employed
-46.6%
Return on sales
-633.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DCPH stock price

How has the Deciphera Pharmaceuticals stock price performed over time
Intraday
-1.55%
1 week
-6.98%
1 month
-7.7%
1 year
-19.82%
YTD
-24.37%
QTD
-24.37%

Financial performance

How have Deciphera Pharmaceuticals's revenue and profit performed over time
Revenue
$42.09M
Gross profit
$41.86M
Operating income
-$271.19M
Net income
-$266.49M
Gross margin
99.5%
Net margin
-633.2%
Deciphera Pharmaceuticals's revenue has surged by 86% QoQ and by 68% YoY
The gross profit has soared by 86% since the previous quarter and by 67% year-on-year
The company's operating margin rose by 48% QoQ and by 20% YoY
The net margin has increased by 47% since the previous quarter and by 18% year-on-year

Growth

What is Deciphera Pharmaceuticals's growth rate over time

Valuation

What is Deciphera Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.52
P/S
57.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
56.61
The company's EPS fell by 7% YoY but it rose by 5% QoQ
The P/B is 10% below the last 4 quarters average of 5.0
Deciphera Pharmaceuticals's equity has decreased by 4.5% QoQ
Deciphera Pharmaceuticals's revenue has surged by 86% QoQ and by 68% YoY
DCPH's price to sales (P/S) is 70% less than its last 4 quarters average of 189.6

Efficiency

How efficient is Deciphera Pharmaceuticals business performance
The company's return on sales rose by 47% QoQ and by 18% YoY
Deciphera Pharmaceuticals's return on invested capital has increased by 13% YoY and by 2.2% QoQ
The ROA has grown by 8% YoY and by 2.2% from the previous quarter
The return on equity has grown by 7% year-on-year

Dividends

What is DCPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DCPH.

Financial health

How did Deciphera Pharmaceuticals financials performed over time
The company's total liabilities rose by 30% YoY and by 9% QoQ
Deciphera Pharmaceuticals's quick ratio has decreased by 16% YoY and by 11% from the previous quarter
The debt is 94% smaller than the equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.